# AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

> **NCT02511795** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 128 (actual)

## Conditions studied

- Refractory Solid Tumours
- Relapsed Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** AZD1775
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02511795
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-06
- **Primary completion:** 2019-04-25
- **Final completion:** 2019-10-16
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511795, "AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02511795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*